Figure 1 The FcγRIIa-H ADCP Reporter Bioassay reflects the MOA and specificity of antibodies designed to bind and activate FcγRIIa-H. Panels A and B. Increasing concentrations of trastuzumab (anti-HER2) or rituximab (anti-CD20) were incubated with either SKBR3 (HER2+) or Raji (CD20+) target cells and FcγRIIa-H Eff ector Cells, as indicated.
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.